UK approves finerenone for a common form of chronic heart failure

Contributed by: Bayer plc

Tags

Bayer UK

Heart Failure

More Like This

UK approves finerenone for a common form of chronic heart failure

MORE PATIENTS ACROSS ENGLAND AND WALES ARE SET TO BECOME ELIGIBLE FOR ASTRAZENECA’S FORXIGA (DAPAGLIFLOZIN) FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

PR Newswire associated0

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

PR Newswire associated0

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

PR Newswire associated0

Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)